Acryl Wins Consecutive National Medical AI R&D Projects

Acryl has consecutively won national projects for medical artificial intelligence (AI) research, development, and demonstration.

According to Acryl on September 4, the core of this project is to connect multimodal medical data—including medical imaging, pathology, genomic, laboratory, and clinical records, which are dispersed across hospitals—using AI, and to establish a full-cycle medical AI system that supports everything from cancer screening and diagnosis to treatment, prognosis, and recurrence management. Through this initiative, Acryl plans to gradually secure a cancer-specific foundation model, a software as a medical device (SaMD) for early diagnosis and recurrence prediction, and agentic AI to support healthcare professionals in decision-making and patient management.

In the field of brain tumors, Acryl will collaborate with Korea University Anam Hospital to develop a multimodal foundation model that integrates and analyzes various medical data such as medical imaging, clinical, and pathology information. Based on this model, the company aims to predict patient survival and risk of recurrence, and to secure AI-based core technologies specializing in healthcare that can be extended to a range of neurological diseases.

In the area of pancreatic cancer, Acryl will participate in the "OnKoTECT" consortium, led by Seoul National University Bundang Hospital, to develop SaMDs for early screening, diagnosis, and postoperative recurrence prediction, using imaging, genomic, pathology, and clinical data. The goal is to implement multimodal predictive technology that comprehensively analyzes diverse patient information with AI, and to pursue its application and regulatory approval in clinical settings.

For lung cancer, Acryl will work with Seoul National University Hospital to develop an agentic AI-based cancer patient management service that integrates and analyzes diagnostic, laboratory, and treatment information to support healthcare professionals’ decision-making. The project aims to support treatment direction decisions in multidisciplinary care processes and to manage patient symptoms, prognosis, and risk of recurrence after treatment. The company will also conduct real-world validation to ensure that patients diagnosed and treated at tertiary hospitals in Seoul can receive follow-up care at regional medical institutions such as Kangwon National University Hospital, with the goal of realizing a regionally integrated cancer management model connecting tertiary hospitals, regional hospitals, and patients.

Jin Park, CEO of Acryl, stated, "Although the recently secured projects target different diseases—brain tumors, pancreatic cancer, and lung cancer—the ultimate goal is the same. What sets Acryl apart is not stopping at individual AI model development, but building the Cancer AX platform that connects the entire patient journey with AI, from screening to diagnosis, treatment, and prognosis management."

This content was produced with the assistance of AI translation services.